Comments*

 
  • Biochemical Pharmacology Discussion Group

    The Biochemical Pharmacology Discussion Group represents a diverse group of scientists from pharmaceutical and biotechnology companies and university and medical research centers interested in biochemistry, molecular biology, biomedical research, and related areas. The group brings together diverse institutions and communities, industrial and academic, to share new and relevant information at the frontiers of research and development. The group also serves as the Biochemical Topical Group for the American Chemical Society's New York Chapter.

  • Upcoming Events

    Wednesday, July 13, 2016 | 9:00 AM - 5:00 PM

    MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications

    Keynote Speaker: David Bartel (Whitehead/MIT/HHMI)
    Speakers: Paul Grint (Regulus Therapeutics), David S Hong (The University of Texas MD Anderson Cancer Center ), Daniel J Siegwart (University of Texas Southwestern Medical Center), Frank Slack (BIDMC Cancer Center/Harvard Medical School), James W Welsh (The University of Texas MD Anderson Cancer Center)

    miRNAs play critical roles in regulating gene expression. This symposium will present up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.

    Thursday, September 8, 2016 | 8:00 AM - 5:00 PM

    Targeting Inflammation and Podocytopathy in Chronic Kidney Disease

    Speakers: Hans-Joachim Anders (Klinikum der Universität München), Caroline Fox (Merck Research Labs), John Cijiang He (The Mount Sinai Medical Center), Matthias Kretzler (University of Michigan), Kevin V Lemley (University of Southern California), Roger C. Wiggins (University of Michigan), Jochen Reiser (RUSH University)

    Accumulating evidence supports a role for renal inflammation and podocytopathy in pathogenesis and progression of chronic kidney disease. This symposium will delve into the mechanisms underlying this pathology.

    Tuesday, October 25, 2016 | 9:00 AM - 5:00 PM

    Emerging Paradigms in Drug Discovery & Chemical Biology

    Speakers: Marcus Bantscheff (Cellzome/GSK), Benjamin F Cravatt (The Scripps Research Institute), Craig Crews (Yale University), Howard Hang (The Rockefeller University), Ruth Nussinov (National Cancer Institute), Brian Raymer (Pfizer), Bryan Roth (University of North Carolina), Eranthie Weerapana (Boston College)

    Chemical Biology is changing the face of drug discovery. This symposium will highlight recent developments in the field, featuring examples from neurobiology and cancer, the ubiquitin proteasome system, GPCRs, and protein lipidation.

    Tuesday, November 15, 2016 | 9:00 AM - 5:00 PM

    Mucosal Healing of the Intestinal Epithelial Barrier

    Speakers: Thaddeus Stappenbeck (Washington University School of Medicine), Declan F. McCole (University of California, Riverside), Jerrold R. Turner (Harvard Medical School), Linda G. Griffith (MIT), and Alan Hanash (Memorial Sloan Kettering Cancer Center)

    This symposium will evaluate emerging research investigating the benefits of achieving mucosal healing in the treatment of intestinal disorders.

    Tuesday, December 6, 2016 | 9:00 AM - 5:00 PM

    Alzheimer's Disease as a Neurovascular Inflammatory Disorder

    Speakers: Katerina Akassoglou (University of California San Francisco), Robert Dempsey (University of Wisconsin), Paula Grammas (University of Rhode Island), Steven Greenberg (Harvard Medical School), Jaime Grutzendler (Yale University), Costantino Iadecola (Weill Cornell Medical College), Jeffrey Iliff (Oregon Health & Science University), Berislav V. Zlokovic (University of Southern California)

    This symposium will highlight basic research and clinical science elucidating the mechanisms underlying vascular contributions to cognitive impairment and dementia (VCID).

  • Past Events

    Tuesday, April 26, 2016 | 9:00 AM - 5:00 PM

    Solute Carrier Proteins: Unlocking the Gene-Family for Effective Therapies

    Speakers: Dax Fu (Johns Hopkins School of Medicine), Kathleen M. Giacomini (University of California, San Francisco), Matthias A. Hediger (University of Bern), Avner Schlessinger (Icahn School of Medicine at Mount Sinai), Giulio Superti-Furga (Austrian Academy of Sciences), Ming Zhou (Baylor College of Medicine), and Kim Huard (Pfizer Inc.)

    Solute Carrier Proteins are an untapped resource for drug discovery. This event will discuss breakthroughs in structural biology, cell engineering and metabolomics that hold the promise of "unlocking" this gene family.

    Tuesday, March 22, 2016 | 12:00 PM - 4:00 PM

    Neuronal Connectivity in Brain Function and Disease: Novel Mechanisms and Therapeutic Targets

    Speakers: Wenbiao Gan (NYU Langone Medical Center), Bruce McEwen (Rockefeller University), Eric Nestler (Icahn School of Medicine at Mount Sinai), Amy Robinson (MIT), Bernardo Sabatini (Harvard Medical School), David Sulzer (Columbia University Medical Center)

    Mapping neuronal circuitry provides important insight into mammalian health and disease. This symposium will discuss emerging tools and novel findings that address this important goal.

    Monday, February 22, 2016 | 9:00 AM - 5:00 PM

    Regenerative Medicine: Transitioning Therapeutics from Cells to the Clinic

    Speakers: John F. DiPersio (Washington University School of Medicine), Jonathan D. Glass (Emory University School of Medicine), Edward O. Lanphier (Sangamo BioSciences, Inc.), Jane S. Lebkowski (Asterias Biotherapeutics), Racheli Ofir (Pluristem LTD), Mahendra Rao (Wake Forest University School of Medicine), Thomas Schulz (ViaCyte, Inc.), John D. Sinden (ReNeuron Limited), Katherine Tsokas (Janssen Research & Development)

    Advances in gene editing have driven an explosion of pre-clinical cell-based therapies. This event addresses the need to rethink clinical, regulatory, & manufacturing approaches to accelerate the transition of drugs through the clinic.

    Tuesday, December 8, 2015 | 8:30 AM - 4:45 PM

    GLP-1 Treatment for Diabetes and Beyond

    Speakers: David D'Alessio (Duke University), Richard DiMarchi (Indiana University), Jean-Philippe Fortin (Pfizer Global), Keld Fosgerau (Zealand Pharma A/S), Matthew R. Hayes (Perelman School of Medicine, University of Pennsylvania), George G. Holz (State University of New York), Beat Jucker (GlaxoSmithKline), Dong Seok Kim (National Institute on Aging / Peptron Inc), Lotte Bjerre Knudsen (Novo Nordisk), Patrick M. Sexton (Monash University), Konrad Talbot (Cedars-Sinai Medical Center)

    GLP-1 receptor agonists have improved treatment options in type 2 diabetes, although realizing their promise in other areas remains challenging. This symposium highlights preclinical and clinical breakthroughs and opportunities for drug development.

    Tuesday, October 27, 2015 | 8:00 AM - 5:00 PM

    Phenotypic and Biomarker-Based Drug Discovery

    Speakers: Andras J. Bauer (Boehringer Ingelheim USA), Myles Fennell (Memorial Sloan-Kettering Cancer Center), Michael R. Jackson (Sanford Burnham Prebys Medical Discovery Institute), Jonathan A. Lee (Eli Lilly), Martin Main (AstraZeneca), Friedrich Metzger (F. Hoffmann-La Roche Ltd), Bruce A. Posner (University of Texas, Southwestern Medical Center), Yao Shen (Columbia University), Aravind Subramanian (Broad Institute), Giulio Superti-Furga (Austrian Academy of Sciences), Susanne Swalley (Novartis Institutes for Biomedical Research), Jitao David Zhang (F. Hoffmann-La Roche Ltd.)

    This symposium aims to deepen our understanding of phenotypic drug discovery and to foster the exchange of ideas between industry-based and academic research scientists.

    Tuesday, July 28, 2015 | 8:30 AM - 6:00 PM

    Leveraging Big Data and Predictive Knowledge to Fight Disease

    Speakers: Marc D Chioda (Pfizer Inc), Leonard James (Pfizer Inc), Iya Khalil (GNS Healthcare), Michael Matheny (Vanderbilt University), Jason H. Moore (University of Pennsylvania), Nicholas Tatonetti (Columbia University Medical Center), Craig P. Webb (NuMedii, Inc), Chunhua Weng (Columbia University), Diane Wuest (GNS Healthcare)

    In the era of precision medicine, analyses of large volumes of data are key to developing targeted and effective therapeutics. This symposium explores how big data and predictive knowledge are used to guide drug development and clinical trials.

    Tuesday, May 26, 2015 | 8:30 AM - 4:30 PM

    Quantitative Systems Pharmacology: Progress Towards Integration into Drug Discovery and Development

    Speakers: Richard Allen (Pfizer, Inc.), John Burke (Applied BioMath), Nitin Mehrotra (US Food and Drug Administration), Sian Ratcliffe (Pfizer Inc), Matthew Rizk (Merck & Co, Inc), Tim Rolph (Pfizer, Inc.), Vikram Sinha (US Food and Drug Administration), Peter Sorger (Harvard Medical School), Paul Watkins (Hamner-UNC Institute for Drug Safety Sciences)

    Quantitative Systems Pharmacology (QSP) has been used successfully in drug discovery and development, yet lacks industry-wide adoption. This symposium highlights past successes and future challenges of using QSP in preclinical and clinical research.

    Monday, April 27, 2015 | 8:30 AM - 4:45 PM

    Non-Motor Symptoms: Unraveling the "Invisible" Face of Parkinson’s Disease

    Speakers: Erwan Bezard (University of Bordeaux), Patrik Brundin (Van Andel Institute), Marie-Francoise Chesselet (UCLA), Diane G. Cook (Parkinson's Disease Foundation), Maurizio Facheris (The Michael J. Fox Foundation for Parkinson's Research), Horacio Kaufmann (NYU Langone Medical Center), Olivier Rascol (University of Toulouse), Anna Sauerbier (NPF International Centre of Excellence, Kings College London), Daniel Weintraub (University of Pennsylvania)

    This symposium will review clinical tools for the diagnosis and treatment of non-motor symptoms of Parkinson's disease, discuss the disease mechanisms, and address preclinical models for the development of new therapeutics.

    Tuesday, April 7, 2015 | 8:30 AM - 5:00 PM

    Cytokine-Based Immunotherapies

    Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA)
    Speakers: Renier J. Brentjens (Memorial Sloan Kettering Cancer Center), Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)

    Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.

    Tuesday, March 24, 2015 | 11:45 AM - 4:00 PM

    Positive Allosteric Modulators for Challenging GPCRs: Identification and Optimization

    Speakers: P. Jeffrey Conn (Vanderbilt University), Ron Dror (Stanford University), Christopher Fotsch (Amgen), Corey Hopkins (Vanderbilt University), Whitney Nolte (Pfizer)

    In this symposium, academic and industry scientists will describe the identification, characterization, and development of PAMs for challenging GPCRs.

    Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM

    Harnessing the Potential of Genome Editing for Drug Discovery: Translational Frontiers of in vitro and in vivo Applications

    Speakers: Chad Cowan (Harvard University), James Inglese (National Center for Advancing Translational Sciences, NIH), J. Keith Joung (Massachusetts General Hospital), Randall Platt (Massachusetts Institute of Technology), Yi Yang (Novartis Institutes for Biomedical Research), Lei (Stanley) Qi (University of California San Francisco)

    The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.

    Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM

    Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

    Speakers: Matthew D. Breyer (Eli Lilly and Company), Frank C. Brosius (University of Michigan Medical School), Benjamin D. Humphreys (Brigham and Women's Hospital), Matthias Meier (F. Hoffmann-La Roche Ltd), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania), Aliza Thompson (Food and Drug Administration)

    Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM

    Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Speaker: Michael S. Conte (University of California-San Francisco), Milan Fiala (David Geffen School of Medicine at UCLA), Gabrielle Fredman (Columbia University), Bruce Levy (Harvard University, Brigham and Women's Hospital), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Harvard Medical School), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Brigham & Women's Hospital, Harvard Medical School), Patricia J. Sime (University of Rochester School of Medicine), Rudolph E. Tanzi (Massachusetts General Hospital)

    Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.

    Tuesday, September 30, 2014 | 8:30 AM - 5:00 PM

    Elucidating GPCR Functional Selectivity: Novel Opportunities for Drug Development

    Keynote Speaker: Nobel Laureate Robert J. Lefkowitz (Duke University Medical Center)
    Speakers: John A. Allen (Pfizer), Laura Bohn (The Scripps Research Institute - Florida), Marc G. Caron (Duke University Medical Center), Jonathan A. Javitch (Columbia University and New York State Psychiatric Institute), Terry Kenakin (University of North Carolina School of Medicine), Bryan L. Roth (University of North Carolina School of Medicine), JoAnn Trejo (University of California, San Diego), Jonathan D. Violin (Trevena Inc.)

    Hear academic, industry, basic and translational researchers, including Nobel Laureate Robert Lefkowitz (Duke University Medical Center) and discuss the development of functionally selective GPCR-biased ligands for CV and CNS disease drug discovery.

    Tuesday, May 20, 2014 | 8:30 AM - 5:00 PM

    Hot Technologies for Developing Next-Gen Biologics

    Speakers: Timothy Charlebois (Pfizer), David King (AnaptysBio Inc.), William M. Pardridge (Brain Research Institute, UCLA), Steven J. Projan (MedImmune), Sachdev Siddhu (University of Toronto), E. Sally Ward (UT Southwestern), Patrick C. Wilson (The University of Chicago), K. Dane Wittrup (Massachusetts Institute of Technology)

    New technologies are pivotal in developing next-generation biologics. This symposium highlights novel technologies in the discovery of new biologics, elucidating in vivo mechanisms of therapeutic proteins, and manufacturing and delivery processes.

    Tuesday, April 8, 2014 | 8:30 AM - 4:30 PM

    Translational Neuroscience in Psychiatry: Light at the End of the Tunnel

    Speakers: Dan V. Iosifescu (Icahn School of Medicine at Mount Sinai), Daniel C. Javitt (Columbia University and Nathan Kline Institute), John H. Krystal (Yale University), Andrew F. Leuchter (University of California, Los Angeles), Gregory Light (University of California, San Diego), Siva Digavalli (Bristol-Myers Squibb), Eva Redei (Northwestern University), Steven J. Siegel (University of Pennsylvania)

    Recent breakthrough insights from clinical studies are illuminating the neurobiology of psychiatric disorders. This symposium explores differences in sensory processing, imaging, and other biomarkers that may translate findings to animal models.

    Tuesday, March 25, 2014 | 12:00 PM - 4:00 PM

    Lung Cancer: Advances in Current Treatment Modalities and Patient Classification

    Speakers: Rolf Brekken (UT Southwestern), Jessica S. Donington (NYU Langone Medical Center), Balazs Halmos (Columbia University Medical Center), Roy S. Herbst (Yale School of Medicine), Suresh S. Ramalingam (Emory University)

    Recent treatment advances may improve lung cancer patient survival rates, as understanding genetic heterogeneity can improve trial patient selection. Hear updates on common mutations, intraoperative chemotherapy, and insights from clinical trials.

    Tuesday, February 18, 2014 | 8:30 AM - 4:30 PM

    Strategies to Inhibit Graft-Versus-Host Disease While Sparing the Graft-Versus-Tumor Response: Finding the Sweet Spot

    Speakers: John DiPersio (Washington University School of Medicine), William R. Drobyski (Medical College of Wisconsin), James Ferrara (University of Michigan), David L. Porter, MD, University of Pennsylvania Medical Center, Robert J. Soiffer (Dana-Farber Cancer Institute), Megan Sykes (Columbia University), Marcel RM van den Brink (Memorial Sloan Kettering Cancer Center)

    Mechanisms that cause graft-versus-host disease (GvHD), a major cause of mortality after stem cell transplants, must be inhibited while preserving the graft-versus-tumor (GvT) response. Explore recent advances in separating GvHD from GvT effects.

    Tuesday, January 28, 2014 | 8:30 AM - 4:30 PM

    Antibody-Drug Conjugates: An Emerging Modality for the Treatment of Cancer

    Speakers: Nahor Haddish-Berhane (Pfizer), Sara Hurvitz (UCLA Medical Center), Omar Kabbarah (Genentech Inc.), Peter D. Senter (Seattle Genetics, Inc.), Dhaval K. Shah (The State University of New York at Buffalo), Stacey S. Shord (Food and Drug Administration), Melissa M. Schutten (Genentech Inc.), and Puja Sapra (Pfizer), Alan Wahl (Ambrx)

    Antibody-drug conjugates (ADCs) promise safer, more effective therapies than standard anti-cancer drugs. This symposium highlights linker-payload and coupling chemistries, ADC development, biomarker and patient selection, and regulatory perspectives.

    Tuesday, December 10, 2013 | 8:30 AM - 4:30 PM

    A Truce in the BAP-tist/Tau-ist War? Progress Toward A Unified Understanding of Alzheimer's Disease

    Speakers: Frank M. LaFerla (University of California, Irvine), Sylvain E. Lesné (University of Minnesota), Bingwei Lu (Stanford University School of Medicine), Lennart Mucke (Gladstone Institute of Neurological Disease), Ralph A. Nixon (Nathan Kline Institute), Franck Polleux (Columbia University), Terrence Town (University of Southern California), Tony Wyss-Coray (Stanford University School of Medicine)
    Organizers: Ken Jones (Forest Research Institute), Robert Martone (Covance Biomarker Center of Excellence), Robert B. Nelson (Lundbeck Research USA), Jennifer Henry (The New York Academy of Sciences)

    This symposium explores how efforts to better integrate our understanding of neuritic plaques and neurofibrillary tangles—the two hallmark pathologies of Alzheimer's disease—are leading to a 'truce' between former rivals in the quest for therapies.

  • Steering Committee

    Lynn M. Abell, PhD

    Bristol-Myers Squibb

    Magdalena Alonso-Galicia, PhD
    Ildiko Antal, PhD

    Bristol-Myers Squibb
    Cochair

    Joshua Apgar, PhD

    Applied BioMath

    Mercedes Beyna, MS

    Biogen

    Ruth Duffy, PhD

    Otsuka America Pharmaceutical, Inc.

    Thomas Franke, MD, PhD

    NYU Langone Medical Center

    Steven Gross, PhD

    Weill Cornell Medical College
    Cochair

    John Hambor, PhD

    Boehringer-Ingelheim

    Julia Heinrich, PhD

    Bristol-Myers Squibb
    Secretary

    Huiping Jiang, PhD

    Boehringer Ingelheim

    Kenneth Jones, PhD

    Allergan

    Katalin Kauser, MD, PhD, DSc

    Bayer Healthcare

    Scott MacDonnell, PhD

    Regeneron Pharmaceuticals, Inc.

    Charles Lunn, PhD

    Drew University

    Robert Martone

    St. Jude Children's Research Hospital

    Marco Prunotto, PhD

    Hoffmann-La Roche

    JoAnne Saye, PhD

    AstraZeneca Pharmaceuticals LP

    Roland Staal, PhD

    New Jersey Economic Development Authority

    Claire M. Steppan, PhD

    Pfizer Worldwide R&D

    W. Ross Tracey, PhD

    Novartis Institutes for BioMedical Research

    Marla Weetall, PhD

    PTC Therapeutics

    Erick R. R. Young, PhD

    Boehringer Ingelheim

    George Zavoico, PhD

    Jones Trading


  • Sponsors

    The Biochemical Pharmacology Discussion Group is proudly supported by:

    • Boehringer Ingelheim

    Premiere Supporter

    • Pfizer

    Get more information about how you can sponsor a discussion group.

    EmailPrint